2023
Real-World Treatment Patterns, Overall Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients with Mantle Cell Lymphoma (MCL) after Failure of Covalent Btki Treatment
Squires P, Puckett J, Ryland K, Kamal-Bahl S, Raut M, Doshi J, Huntington S. Real-World Treatment Patterns, Overall Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients with Mantle Cell Lymphoma (MCL) after Failure of Covalent Btki Treatment. Blood 2023, 142: 2326. DOI: 10.1182/blood-2023-181024.Peer-Reviewed Original ResearchR mantle cell lymphomaHealthcare resource useLines of therapyMantle cell lymphomaMedian overall survivalOverall survivalTreatment initiationElderly patientsTyrosine kinase inhibitorsTreatment patternsPrior linesStandard chemotherapyU.S. patientsCell lymphomaReal-world treatment patternsRefractory mantle cell lymphomaBruton tyrosine kinase inhibitorsCause total costsFourth-line treatmentService Medicare coverageThird-line settingProgression-free survivalHalf of patientsHealthcare resource utilizationLarge unmet needReal-World Patterns of Targeted Therapy Use in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma in the United States: A Longitudinal Study
De Nigris E, Cheng W, Sarpong E, Leng S, Farooqui M, Agu U, Catillon M, Lejeune D, Downes N, Matay L, Duh M, Huntington S. Real-World Patterns of Targeted Therapy Use in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma in the United States: A Longitudinal Study. Blood 2023, 142: 6523. DOI: 10.1182/blood-2023-178660.Peer-Reviewed Original ResearchB-cell lymphoma-2 inhibitorBruton tyrosine kinase inhibitorsProportion of patientsCLL/SLLSmall lymphocytic lymphomaTyrosine kinase inhibitorsLymphocytic lymphomaNew agentsChronic lymphocytic leukemia/small lymphocytic lymphomaMedian age 73 yearsOptum Clinformatics DataMart databaseClinformatics DataMart databaseEnd of eligibilityObservation periodThird of patientsAge 73 yearsClaims-based algorithmChronic lymphocytic leukemiaTreatment classesReal-world studyNovel Bruton's tyrosine kinase inhibitorEligible patientsIndex dateAdult patientsTargeted agentsReal-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia
Huntington S, Manzoor B, Puckett J, Kamal-Bahl S, Alhasani H, Ravelo A, Jawaid D, Doshi J. Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia. Leukemia & Lymphoma 2023, 64: 2316-2323. PMID: 37732602, DOI: 10.1080/10428194.2023.2255326.Peer-Reviewed Original ResearchConceptsChronic lymphocytic leukemiaReal-world adherenceRefractory chronic lymphocytic leukemiaTyrosine kinase inhibitorsLymphocytic leukemiaB-cell lymphoma-2 inhibitorBruton tyrosine kinase inhibitorsNovel oral agentsClinical trial dataOral agentsClinical characteristicsElderly patientsTreatment landscapeTreatment initiationReal-world findingsHigh adherenceMedicare beneficiariesLower discontinuationTrial dataDiscontinuationPatientsOlder adultsKinase inhibitorsAdherenceLeukemiaDTRMWXHS‐12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open‐label, multicenter, phase 1a/1b study
Huntington S, Schuster S, Ding W, Koehler A, Brander D, Rosenthal A, Leis J, Tun H, Moustafa M, Iqbal M, He W, Kearney A, McKinlay T, Gui M, Mato A. DTRMWXHS‐12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open‐label, multicenter, phase 1a/1b study. American Journal Of Hematology 2023, 98: 739-749. PMID: 36810799, DOI: 10.1002/ajh.26888.Peer-Reviewed Original ResearchConceptsBruton tyrosine kinase inhibitorsTyrosine kinase inhibitorsRefractory lymphomaTriplet combinationsKinase inhibitorsOral combination therapyPhase 2 doseOpen-label studyDose-escalation studyAccelerated titration designB-cell NHLNovel Bruton's tyrosine kinase inhibitorEligible patientsEverolimus 5Refractory CLLEscalation studyTriplet therapyMedian ageCombination therapyHodgkin's lymphomaIMiD therapyImmunomodulatory agentsClinical activityDoublet combinationsPreclinical studies
2021
Favorable Outcomes for Patients Treated with U2 with Co-Morbidities or Concomitant Medications: A Retrospective Analysis of Unity-CLL Phase 3 Trial
Ibarz J, Jurczak W, Kambhampati S, Maranda E, Wróbel T, Sharman J, Zafar S, Hoffmann M, Huntington S, Jacobs R, Bairey O, Rowland C, Miskin H, Sportelli P, Weiss M, O'Connor O, Flinn I. Favorable Outcomes for Patients Treated with U2 with Co-Morbidities or Concomitant Medications: A Retrospective Analysis of Unity-CLL Phase 3 Trial. Blood 2021, 138: 3748. DOI: 10.1182/blood-2021-151292.Peer-Reviewed Original ResearchSarah Cannon Research InstituteBruton tyrosine kinase inhibitorsProgression-free survivalOverall response rateChronic lymphocytic leukemiaCurrent equity holderUndetectable minimal residual diseaseConcomitant medicationsTreatment-naïveRisk factorsTyrosine kinase inhibitorsMedian ageSpeakers bureauDay 1Median progression-free survivalSuperior progression-free survivalSimilar overall response ratesAdvisory CommitteeAdequate organ functionIncidence of SAEsMultiple concomitant medicationsPre-existing comorbidityBaseline disease characteristicsKey secondary endpointDurable clinical benefit
2020
Outcomes of COVID-19 in patients with CLL: a multicenter international experience
Mato AR, Roeker LE, Lamanna N, Allan JN, Leslie L, Pagel JM, Patel K, Osterborg A, Wojenski D, Kamdar M, Huntington SF, Davids MS, Brown JR, Antic D, Jacobs R, Ahn IE, Pu J, Isaac KM, Barr PM, Ujjani CS, Geyer MB, Berman E, Zelenetz AD, Malakhov N, Furman RR, Koropsak M, Bailey N, Hanson L, Perini GF, Ma S, Ryan CE, Wiestner A, Portell CA, Shadman M, Chong EA, Brander DM, Sundaram S, Seddon AN, Seymour E, Patel M, Martinez-Calle N, Munir T, Walewska R, Broom A, Walter H, El-Sharkawi D, Parry H, Wilson MR, Patten PEM, Hernández-Rivas JÁ, Miras F, Fernández Escalada N, Ghione P, Nabhan C, Lebowitz S, Bhavsar E, López-Jiménez J, Naya D, Garcia-Marco JA, Skånland SS, Cordoba R, Eyre TA. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood 2020, 136: 1134-1143. PMID: 32688395, PMCID: PMC7472711, DOI: 10.1182/blood.2020006965.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgammaglobulinaemia Tyrosine KinaseAgedAged, 80 and overAnti-Inflammatory AgentsAntiviral AgentsBetacoronavirusCoronavirus InfectionsCOVID-19COVID-19 SerotherapyFemaleHumansImmunization, PassiveLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedPandemicsPneumonia, ViralProtein Kinase InhibitorsSARS-CoV-2Survival AnalysisTreatment OutcomeConceptsCOVID-19 diagnosisCLL patientsHigh riskCumulative Illness Rating Scale scoreCOVID-19Intensive care unit admissionOverall case fatality rateChronic lymphocytic leukemia patientsBruton tyrosine kinase inhibitorsMulticenter international experienceCare unit admissionSymptomatic COVID-19Severe acute respiratory syndrome coronavirus 2 infection riskCOVID-19 courseCase fatality rateRating Scale scoresFuture epidemiologic studiesLymphocytic leukemia patientsCoronavirus disease 2019Tyrosine kinase inhibitorsUnit admissionBaseline characteristicsMost patientsHospital admissionImmune dysfunction
2019
Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States
Huntington S, Soulos P, Barr P, Jacobs R, Lansigan F, Odejide O, Schwartzberg L, Davidoff A, Gross C. Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States. Blood 2019, 134: 797. DOI: 10.1182/blood-2019-122054.Peer-Reviewed Original ResearchFirst-line settingChronic lymphocytic leukemiaFlatiron Health databaseECOG performance statusFirst-line treatmentEarly discontinuationMultivariable logistic regressionPerformance statusIbrutinib discontinuationSpeakers bureauClinical trialsCLL diagnosisCLL therapyLymphocytic leukemiaHealth databasesLogistic regressionBruton tyrosine kinase inhibitorsFirst-line ibrutinibUse of ibrutinibWorse performance statusPoor performance statusRetrospective cohort studyCommunity oncology settingClinical decision support toolCommunity oncology practices